Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab has reported that its partner Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma.
Subscribe to our email newsletter
The R1507 antibody was created by Genmab under the company’s agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of $500,000.
Lisa Drakeman, CEO of Genmab, said: “R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development. We believe that R1507 may offer an additional treatment option to sarcoma patients.”